^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR exon 19 mutation

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over1year
    Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report. (PubMed, J Drug Target)
    A small number of documented cases of tSCLC after immunotherapy highlight the need for rebiopsies at progression to diagnose this potential resistance mechanism. Further research is needed to better understand the mechanisms underlying this phenomenon and to develop more effective treatment strategies for patients with tSCLC.
    Review • Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 19 mutation • EGFR positive
    2years
    An in vitro model and the underlying pathways of sinonasal inverted papilloma development. (PubMed, Sci Rep)
    These results suggest that specific mutations in EGFR exon 20 play a crucial role in SIP development, partially though hyper-activation of the PI3K/AKT and MAPK signaling pathways. This study presents the first in vitro model for SIP development, which could facilitate further investigations into SIP pathogenesis and preclinical studies for new therapeutic agents.
    Preclinical • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR expression • EGFR exon 19 mutation • EGFR exon 20 mutation • EGFR E746 • EGFR S768_D770dup
    over2years
    RIGHT VENTRICULAR OUTFLOW TRACT OBSTRUCTION SECONDARY TO METASTATIC PULMONARY ADENOCARCINOMA (CHEST 2023)
    She had a recent diagnosis of pulmonary embolism treated with apixaban... RVOTO from tumor mass effect should be on the differential of patients with metastatic primary lung cancer presenting with new orthostatic signs and symptoms.
    Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 19 mutation
    3years
    Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation. (PubMed, Cancers (Basel))
    Similarly, mutations in NRAS and HRAS were more frequently detected in samples from tumors harboring mutations in exons 18 or 21 (Fisher p-value: 0.050 and Fisher p-value: 0.099, respectively). In conclusion, our data suggest that the mechanisms underlying EGFR-TKI resistance could be dependent on the exon location of the original EGFR-sensitizing mutation.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • FGFR3 (Fibroblast growth factor receptor 3) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    TP53 mutation • KRAS mutation • EGFR mutation • NRAS mutation • EGFR T790M • EGFR exon 19 mutation • HRAS mutation • EGFR positive • EGFR exon 18 mutation
    |
    Oncomine™ Pan-Cancer Cell-Free Assay
    over3years
    Use of thyroid transcription factor 1 and napsin A to predict local failure and survival after Gamma Knife radiosurgery in patients with brain metastases from lung adenocarcinoma. (PubMed, J Neurosurg)
    Pathological biomarkers of primary cancer should be considered to predict clinical outcomes after SRS in patients with lung ADC. Use of such biomarkers may help to provide personalized treatment to each patient, improving clinical outcomes after SRS.
    Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • NKX2-1 (NK2 Homeobox 1) • NAPSA (Napsin A Aspartic Peptidase)
    |
    EGFR mutation • EGFR exon 21 mutation • EGFR exon 19 mutation
    over3years
    Clinical and Radiological Characteristics to Differentiate Between EGFR Exon 21 and Exon 19 Mutations in Patients With Lung Adenocarcinoma: A Systematic Literature Review and Meta-Analysis. (PubMed, Cureus)
    Specific EGFR exon 21 and 19 mutations cannot be differentiated through characteristics (absence of smoking status and female sex) or radiological patterns (GGO, air bronchogram, pleural retraction, and speculation). There is limited data to assess if early disease stage or vascular convergence aids in differentiating exon 21 from 19 mutations in patients with lung adenocarcinoma.
    Retrospective data • Review • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 19 mutation
    4years
    The pathological tissue expression pattern and clinical significance of m6A-regulatory genes in non-small cell lung cancer. (PubMed, J Gene Med)
    Our results indicate that m6A regulators, including METTL3, ALKBH5, YTHDC2, and YTHDF1, could serve as predictive markers of NSCLC, which will facilitate early detection and diagnosis of NSCLC.
    Clinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • ALKBH5 (AlkB Homolog 5, RNA Demethylase) • METTL3 (Methyltransferase Like 3)
    |
    TP53 mutation • KRAS mutation • EGFR mutation • EGFR exon 19 mutation
    4years
    Gastric metastasis and transformation of primary lung adenocarcinoma to small cell cancer after acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors: A case report. (PubMed, Medicine (Baltimore))
    Timely second biopsies should be considered in the diagnosis of phenotypic transformation. After transformation, chemotherapeutic treatment with etoposide and platinum and maintenance therapy with osimertinib inhibited the progression of the disease.
    Clinical • Preclinical • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M • EGFR exon 19 mutation
    |
    Tagrisso (osimertinib) • gefitinib • etoposide IV